Typhoid fever is an infectious disease which is caused by the bacterium Salmonella typhi. The disease remains a significant global health concern, particularly in developing countries. With over 10 Mn cases reported each year, it is crucial to explore effective preventive measures, the most important being the oral typhoid vaccine.
The oral typhoid vaccine which is also known as Ty21a, has gained popularity due to its convenience and effectiveness in preventing typhoid fever. Unlike traditional injectable vaccines, this innovative vaccine is administered orally, thus making it easier to distribute and administer, especially in areas with limited healthcare facilities.
The oral typhoid vaccine market is driven by several factors. Firstly, the increasing incidence of typhoid fever has created a need for effective preventive measures, thereby boosting the demand for oral typhoid vaccines. Growing awareness about the benefits of vaccination and the importance of public health initiatives has contributed to market growth.
However, there are also certain restraints to the market. One such challenge is the limited access to healthcare services in many regions, which hinders the distribution and administration of oral typhoid vaccines. Moreover, the high cost associated with vaccine production and distribution poses a barrier to reaching underserved populations.
Despite these challenges, the oral typhoid vaccine market holds promising opportunities for growth. The development of cost-effective manufacturing processes and streamlined distribution networks can help overcome access barriers. Furthermore, ongoing research and development (R&D) efforts to enhance the efficacy and safety of oral typhoid vaccines can drive market expansion.
Key features of the study:
- This report provides in-depth analysis of the oral typhoid vaccine market, and provides market size (US$ Mn ) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global oral typhoid vaccine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include oral typhoid vaccine market include Janssen Global Services, LLC, EMERGENT, Berna Biotech AG, Daewoong Pharmaceutical, and Bavarian Nordic
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The oral typhoid vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the oral typhoid vaccine market
- Oral Typhoid Vaccine Market, By Distribution Channel
- Hospitals and Clinics
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Government Immunization Programs etc.)
- Oral Typhoid Vaccine Market, By Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Top Companies in Oral Typhoid Vaccine Market:
- Janssen Global Services, LLC
- Berna Biotech AG
- Daewoong Pharmaceutical
- Bavarian Nordic